A new review of previous scientific studies has concluded that stem cell therapy may help reduce the number of deaths in heart patients.

The Cochrane Heart Review Group analyzed data from studies involving just over 1,200 patients in 23 randomized, controlled trials.

The group's report on the potential benefits of stem cell heart repair was published online on April 29 in The Cochrane Library. The Cochrane Reviews are systematic assessments of evidence-based research into human health care and health policy.

There were fewer deaths among heart patients receiving stem cell therapy in addition to standard treatment, compared to patients who were treated with traditional therapies alone or with a placebo. Stem cells are primitive master cells that, under the right conditions, can turn into any cell in the body.

The therapy also reduced the chances that patients, with improved heart function, had to be readmitted to the hospital.

The review noted that stem cell therapy could possibly reduce the number of deaths after one year, but the results of larger clinical trials are needed.

The stem cells are taken from a patients own bone marrow and injected into the hearts of patients with ischemic heart disease and congestive heart failure, repairing damaged cardiac tissue.

Dr. Enca Martin-Rendon, author of the review in Britain, said, This is encouraging evidence that stem cell therapy has benefits for heart disease patients. However, Martin-Rendon noted it is difficult to come to any concrete conclusions until larger clinical trials are carried out.

The rest is here:

Stem Therapy May Improve Survival of Heart Patients

TWIS Minion / Science Island Hangout - May 1, 2014
Ed Dyer, Ulysses Adkins and Jani Turunen talking about Ganymede #39;s "club sandwich" oceans, NASA #39;s space life rafts, stem cells therapy regenerating heart muscles, blood and cartilage. Show...

By: Edward Dyer

Read more:

TWIS Minion / Science Island Hangout - May 1, 2014 - Video

April Flowers for redOrbit.com Your Universe Online

A new study, from the Stanford University School of Medicine and Montana State University, demonstrates that, when implanted into the reproductive system of a mouse model, stem cells created from adult, infertile men will yield primordial germ cells. Primordial germ cells normally become sperm cells.

The findings, published in Cell Reports, help to further our understanding of a genetic cause of male infertility and basic sperm biology. The research team says that their approach holds considerable potential for clinical applications.

All of the infertile male participants suffer from a genetic mutation that prevents their bodies from producing mature sperm. The study suggests that the men with this condition called azoospermia might have produced germ cells at some point in their early lives, but these cells were lost as the men matured to adulthood.

Our results are the first to offer an experimental model to study sperm development, said Renee Reijo Pera of the Institute for Stem Cell Biology & Regenerative Medicine and Montana State University. Therefore, there is potential for applications to cell-based therapies in the clinic, for example, for the generation of higher quality and numbers of sperm in a dish.

It might even be possible to transplant stem-cell-derived germ cells directly into the testes of men with problems producing sperm, she added. Considerable study to ensure safety and practicality is needed, however, before reaching that point.

Infertility is a fairly common problem, affecting between 10 and 15 percent of couples in the US. The researchers say that many men are affected by genetic causes of infertility, most commonly due to the spontaneous loss of key genes on the Y sex chromosome. Until now, the causes of infertility at the molecular level have not been clear.

The fact that the research team was able to create primordial germ cells from the infertile men is very promising, but they note that these stem cells created far fewer of these sperm progenitors than the stem cells of men without the genetic mutations. They are sure, however, that this research provides a much needed model to study the earliest steps of human reproduction.

We saw better germ-cell differentiation in this transplantation model than weve ever seen, said Reijo Pera, former director of Stanfords Center for Human Embryonic Stem Cell Research and Education. We were amazed by the efficiency. Our dream is to use this model to make a genetic map of human germ-cell differentiation, including some of the very earliest stages.

Humans share many cellular and physiological processes with common laboratory animals such as mice or fruit flies. In reproduction, however, there are significant variances, making it challenging to recreate the human reproductive processes in a laboratory setting. In addition, many crucial steps, such as the development and migration of primordial germ cells to the gonads,occur in the relatively short first days or weeks after conception.

Read more:

Stem Cells Of Infertile Men Used To Create Preliminary Sperm Cells

New York, NY (PRWEB) May 02, 2014

Stem Cell Institute is releasing additional tickets for its Adult Stem Cell Therapy Clinical Trials seminar on Saturday, May 17, 2014 in New York City at the New York Hilton Midtown from 1:00 pm to 4:00 pm.

After booking its original meeting room beyond capacity, the Stem Cell Institute has reserved a larger room to accommodate additional attendees. The seminar will now take place in the Beekman Room, 2nd Floor, East Corridor of the New York Hilton Midtown.

Those interested in attending are encouraged to register promptly. Only 75 additional seats are available.

Speakers include:

Neil Riordan PhD Clinical Trials: Umbilical Cord Mesenchymal Stem Cell Therapy for Autism and Spinal Cord Injury

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD Stem Cell Therapy for Autoimmune Disease: MS, Rheumatoid Arthritis and Lupus

Dr. Paz is the Medical Director at the Stem Cell Institute. He practiced internal medicine in the United States for over a decade before joining the Stem Cell Institute in Panama.

Special guest speaker:

The rest is here:

Additional Tickets Released for Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in New ...

University of Adelaide researchers have discovered that stem cells taken from teeth can grow to resemble brain cells, suggesting they could one day be used in the brain as a therapy for stroke.

In the University's Centre for Stem Cell Research, laboratory studies have shown that stem cells from teeth can develop and form complex networks of brain-like cells. Although these cells haven't developed into fully fledged neurons, researchers believe it's just a matter of time and the right conditions for it to happen.

"Stem cells from teeth have great potential to grow into new brain or nerve cells, and this could potentially assist with treatments of brain disorders, such as stroke," says Dr Kylie Ellis, Commercial Development Manager with the University's commercial arm, Adelaide Research & Innovation (ARI).

Dr Ellis conducted this research as part of her Physiology PhD studies at the University, before making the step into commercialisation. The results of her work have been published in the journal Stem Cell Research & Therapy.

"The reality is, treatment options available to the thousands of stroke patients every year are limited," Dr Ellis says. "The primary drug treatment available must be administered within hours of a stroke and many people don't have access within that timeframe, because they often can't seek help for some time after the attack.

"Ultimately, we want to be able to use a patient's own stem cells for tailor-made brain therapy that doesn't have the host rejection issues commonly associated with cell-based therapies. Another advantage is that dental pulp stem cell therapy may provide a treatment option available months or even years after the stroke has occurred," she says.

Dr Ellis and her colleagues, Professors Simon Koblar, David O'Carroll and Stan Gronthos, have been working on a laboratory-based model for actual treatment in humans. As part of this research Dr Ellis found that stem cells derived from teeth developed into cells that closely resembled neurons.

"We can do this by providing an environment for the cells that is as close to a normal brain environment as possible, so that instead of becoming cells for teeth they become brain cells," Dr Ellis says.

"What we developed wasn't identical to normal neurons, but the new cells shared very similar properties to neurons. They also formed complex networks and communicated through simple electrical activity, like you might see between cells in the developing brain."

This work with dental pulp stem cells opens up the potential for modelling many more common brain disorders in the laboratory, which could help in developing new treatments and techniques for patients.

See original here:

Stem cells from teeth can make brain-like cells

An implanted graft of cardiac cells derived from human stem cells (green) meshed with a monkey's own heart cells (red). Picture: Murry Lab/University of Washington/PA

Stem cell heart repair treatments could be tested on human patients within four years following a ground-breaking study of monkeys.

Scientists successfully restored damaged cardiac muscle in macaque monkeys suffering the after-effects of experimentally induced heart attacks, paving the way to clinical trials.

Researchers injected 1bn immature heart muscle cells derived from human embryonic stem cells into each animals heart.

Over several weeks, the new cells developed, assembled into muscle fibres, and began to beat in correct time. On average, 40% of the damaged heart tissue was regenerated.

It is the first time stem cell therapy for damage caused by heart attacks has been shown to work in a primate.

Lead scientist Prof Charles Murry, director of the Centre for Cardiovascular Biology at the University of Washington in Seattle, said: Before this study, it was not known if it is possible to produce sufficient numbers of these cells and successfully use them to remuscularise damaged hearts in a large animal whose heart size and physiology is similar to that of the human heart.

He expects the treatment to be ready for clinical trials in human patients within four years.

Heart attack symptoms were triggered in the monkeys by blocking the coronary artery the main artery supplying the heart with blood for 90 minutes.

In humans, the reduced blood flow caused by narrowing of the arteries has a similar effect. Lack of blood flow to the heart damages the heart muscle by depriving it of oxygen.

The rest is here:

Stem cell breakthrough in treating heart attacks

May 1, 2014

Image Caption: This is the distinct neuronal-like appearance of a mouse-derived dental pulp stem cell following the induction process. Credit: Dr. Kylie Ellis, University of Adelaide.

University of Adelaide

University of Adelaide researchers have discovered that stem cells taken from teeth can grow to resemble brain cells, suggesting they could one day be used in the brain as a therapy for stroke.

In the Universitys Centre for Stem Cell Research, laboratory studies have shown that stem cells from teeth can develop and form complex networks of brain-like cells. Although these cells havent developed into fully fledged neurons, researchers believe its just a matter of time and the right conditions for it to happen.

Stem cells from teeth have great potential to grow into new brain or nerve cells, and this could potentially assist with treatments of brain disorders, such as stroke, says Dr Kylie Ellis, Commercial Development Manager with the Universitys commercial arm, Adelaide Research & Innovation (ARI).

Dr Ellis conducted this research as part of her Physiology PhD studies at the University, before making the step into commercialization. The results of her work have been published in the journal Stem Cell Research & Therapy.

The reality is, treatment options available to the thousands of stroke patients every year are limited, Dr Ellis says. The primary drug treatment available must be administered within hours of a stroke and many people dont have access within that timeframe, because they often cant seek help for some time after the attack.

Ultimately, we want to be able to use a patients own stem cells for tailor-made brain therapy that doesnt have the host rejection issues commonly associated with cell-based therapies. Another advantage is that dental pulp stem cell therapy may provide a treatment option available months or even years after the stroke has occurred, she says.

Dr Ellis and her colleagues, Professors Simon Koblar, David OCarroll and Stan Gronthos, have been working on a laboratory-based model for actual treatment in humans. As part of this research Dr Ellis found that stem cells derived from teeth developed into cells that closely resembled neurons.

See the article here:

Stem Cells Taken From Teeth Can Make Brain-like Cells

Stem Cell Treatment In Panama Working Wonders
This is an update on Beverly after only 10 days in Panama for Stem Cell Treatment. She is feeling so much better and you can see it just by the look on her face. She has Secondary Progressive...

By: Stem Cell Patient

View post:

Stem Cell Treatment In Panama Working Wonders - Video

Heart cells created from human embryonic stem cells successfully restored damaged heart muscles in monkeys.

The results of the experiment appear in the April 30 advanced online edition of the journal Nature in a paper titled, "Human embryonic-stem cell derived cardiomyocytes regenerate non-human primate hearts."

The findings suggest that the approach should be feasible in humans, the researchers said.

"Before this study, it was not known if it is possible to produce sufficient numbers of these cells and successfully use them to remuscularize damaged hearts in a large animal whose heart size and physiology is similar to that of the human heart," said Dr. Charles Murry, UW professor of pathology and bioengineering, who led the research team that conducted the experiment.

A physician/scientist, Murry directs the UW Center for Cardiovascular Biology and is a UW Medicine pathologist.

Murry said he expected the approach could be ready for clinical trials in humans within four years.

In the study, Murry, along with Dr. Michael Laflamme and other colleagues at the UW Institute for Stem Cell & Regenerative Medicine, experimentally induced controlled myocardial infarctions, a form of heart attack, in anesthetized pigtail macaques.

The infarcts were created by blocking the coronary artery of macaque for 90 minutes, an established model for the study of myocardial infarction in primates.

In humans, myocardial infarctions are typically caused by coronary artery disease. The resulting lack of adequate blood flow can damage heart muscle and other tissues by depriving them of oxygen. Because the infarcted heart muscle does not grow back, myocardial infarction leaves the heart less able to pump blood and often leads to heart failure, a leading cause of cardiovascular death.

The goal of stem cell therapy is to replace the damaged tissue with new heart cells and restore the failing heart to normal function.

Go here to see the original:

Stem cell therapy regenerates heart muscle damaged from heart attacks in primates

Home > News > health-news

Sydney, May 1 : The humble teeth can come to rescue your brain. Researchers at University of Adelaide have discovered that stem cells taken from teeth can grow to resemble brain cells and can be used in the brain as a therapy for stroke.

"Stem cells from teeth have great potential to grow into new brain or nerve cells and this could potentially assist with treatments of brain disorders, such as stroke," explained Kylie Ellis, a commercial development manager with the University's Adelaide Research & Innovation (ARI).

In the University's centre for stem cell research, lab studies have shown that stem cells from teeth can develop and form complex networks of brain-like cells.

The reality is that treatment options available to the thousands of stroke patients every year are limited.

"Ultimately, we want to be able to use a patient's own stem cells for tailor-made brain therapy that does not have the host rejection issues commonly associated with cell-based therapies," Ellis noted.

Another advantage is that dental pulp stem cell therapy may provide a treatment option available months or even years after the stroke has occurred, she added.

"We can do this by providing an environment for the cells that is as close to a normal brain environment as possible, so that instead of becoming cells for teeth, they become brain cells," Ellis maintained.

This work with dental pulp stem cells opens up the potential for modelling many more common brain disorders in the laboratory, which could help in developing new treatments and techniques for patients.

The results of her work were published in the journal Stem Cell Research & Therapy.

See original here:

Teeth stem cells can help treat brain stroke

Stem cell therapy | irish stem cells
http://www.arthritistreatmentcenter.com So what #39;s going on in Ireland when it comes to arthritis... coming up next... First signs of arthritis cure seen by I...

By: Nathan Wei

Link:

Stem cell therapy | irish stem cells - Video

PUBLIC RELEASE DATE:

28-Apr-2014

Contact: Franca Davenport f.davenport@imperial.ac.uk 020-759-42198 Imperial College London

New research looking at the success of clinical trials of stem cell therapy shows that trials appear to be more successful in studies where there are more discrepancies in the trial data.

Researchers from Imperial College London conducted a meta-analysis of 49 randomised controlled trials of bone marrow stem cell therapy for heart disease. The study, published today in the British Medical Journal, identified and listed over 600 discrepancies within the trial reports.

Discrepancies were defined as two (or more) reported facts that could not both be accurate because they were logically or mathematically incompatible. For example, one trial reported that it involved 70 patients, who were divided into two groups of 35 and 80.

The researchers found eight trials that each contained over 20 discrepancies.

The researchers found that the discrepancy count in a trial was the most important determinant of the improvement in cardiac function reported by that trial. Trials with fewer and fewer discrepancies showed progressively smaller improvements in cardiac function. The five trials with no discrepancies at all showed an effect size of zero (see bar chart in Notes to Editors).

Previous meta-analyses looking at the results of lots of clinical trials have suggested that on average, bone marrow stem cell therapy has a significant positive effect on improving heart function. However, some trials have shown that it successfully improves heart function whilst others have not. The reasons for this are unclear.

Professor Darrel Francis, one of the study authors from the National Heart and Lung Institute at Imperial College London, said: "Clinical trials involve a huge amount of data and so it is understandable that discrepancies sometimes arise when researchers are presenting their findings. However, our study suggests that these discrepancies can have a significant impact on the overall results. It is a powerful reminder to all of us conducting clinical trials to be careful and vigilant to avoid discrepancies appearing in the work.

Continued here:

Study of stem cell trials links discrepancies in data with reported success of treatment

PUBLIC RELEASE DATE:

29-Apr-2014

Contact: Jennifer Beal sciencenewsroom@wiley.com 44-124-377-0633 Wiley

Stem cell therapies work as a complement to standard treatments, potentially cutting the number of deaths after a year, suggests evidence from the latest Cochrane review: Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Taking stem cells from a patient's bone marrow and injecting them into their damaged heart may be an effective way to treat heart disease.

The new review, published today in The Cochrane Library, uses data involving 1,255 people from 23 randomised controlled trials, where all participants received standard treatments. Compared to standard treatment alone or with placebo, stem cell therapy using bone marrow cells resulted in fewer deaths due to heart disease and heart failure, reduced the likelihood of patients being readmitted to hospital, and improved heart function. However, researchers say that with much larger clinical trials underway, the findings are awaited to enable more certainty about the effects.

Dr Enca Martin-Rendon, author of the review, Cochrane Heart Review Group, and based at NHS Blood and Transplant and the University of Oxford, UK, said: "This is encouraging evidence that stem cell therapy has benefits for heart disease patients. However, it is generated from small studies and it is difficult to come to any concrete conclusions until larger clinical trials that look at longer- term effects are carried out."

Stem cell therapies are experimental treatments that are currently only available in facilities carrying out medical research. If eventually found to be effective, they might offer an alternative or complementary treatment to standard drug and surgical treatments for some patients with chronic heart disease. The procedure involves collecting stem cells from a patient's own blood or bone marrow and using them to repair damaged tissues in the patient's heart and arteries.

Although within the first year there were no clear benefits of stem cell therapy over standard treatment alone, when longer term data were analysed a year or more later about 3 per cent of people treated with their stem cells had died compared with 15 per cent of people in the control groups. Hospital readmissions were reduced to 2 in every 100 people compared to 9 in the control group, and adverse effects were rare.

Dr Martin-Rendon continued, "It isn't clear which types of stem cells work best or why stem cell therapies seem to work for some people but not for others. We need to find out what's different in the people who aren't responding well to these treatments as it might then be possible to tailor therapies to these patients, so that they work better."

Dr David Tovey, Editor-in-Chief, Cochrane, said: "This review should help to raise awareness of the potential of stem cell therapy to improve patient outcomes, but it also demonstrates the importance of recognising the uncertainty of initial findings and the need for further research. A Cochrane review aims to analyse all available data to give a clear picture of what the evidence shows. Ensuring health decision makers, health professionals and the general public has access to up-to-date, relevant evidence research will help to raise awareness of the effectiveness of treatments and medications and therefore improve health care."

See the original post here:

Stem cell therapies look promising for heart disease

Chaiwat Subprasom/Reuters/Corbis

Many companies around the world offer stem-cell treatments to patients with heart disease.

An analysis of clinical studies that use adult stem cells to treat heart disease has raised questions about the value of a therapy that many consider inappropriately hyped.

Early-phase clinical trials have reported that adult stem cells are effective in treating heart attack and heart failure, and many companies are moving quickly to tap into this potentially lucrative market. But a comprehensive study that looked at discrepancies in trials investigating treatments that use patients own stem cells, published this week in the journal BMJ (ref. 1), finds that only trials containing flaws, such as design or reporting errors, showed positive outcomes. Error-free trials showed no benefit at all.

The publication comes as two major clinical trials designed to conclusively test the treatments efficacy are recruiting thousands of patients.

The BMJ paper is concerning because the therapeutic approach is already being commercialized, argues stem-cell researcher Paolo Bianco at the Sapienza University of Rome. Premature trials can create unrealistic hopes for patients, and divert resources from the necessary basic studies we need to design more appropriate treatments.

Therapies that use adult stem cells typically involve collecting mesenchymal stem cells from bone marrow taken from the patients hip bone. The cells are then injected back into the patient, to help repair damaged tissue. Original claims that they differentiated into replacement cells have been rejected2, and many clinicians now believe that the cells act by releasing molecules that cause inflammation, with an attendant growth of oxygen-delivering small blood vessels, in the damaged tissue.

The approach has spawned international commercialization of various forms of the therapy, with companies offering treatments for disorders ranging from Parkinsons disease to heart failure. But the effectiveness of such therapies remains unproven.

I have a lot of hope for regenerative medicine, but our results make me fearful.

The BMJ study, led by cardiologist Darrel Francis at Imperial College London, examined 133 reports of 49 randomized clinical trials published up to April last year, involving the treatment of patients who had had a heart attack or heart failure. It included all accessible randomized studies, and looked for discrepancies in design, methodology and reporting of results.

More:

Doubts over heart stem-cell therapy

New York, NY (PRWEB) April 29, 2014

The Stem Cell Institute located in Panama City, Panama, welcomes special guest speaker Roberta F. Shapiro, DO, FAAPM&R to its public seminar on umbilical cord stem cell therapy on Saturday, May 17, 2014 in New York City at the New York Hilton Midtown from 1:00 pm to 4:00 pm.

Dr. Shapiro will discuss A New York Doctors Path to Panama.

Dr. Shapiro operates a private practice for physical medicine and rehabilitation in New York City. Her primary professional activities include outpatient practice focused on comprehensive treatment of acute and chronic musculoskeletal and myofascial pain syndromes using manipulation techniques, trigger point injections, tendon injections, bursae injections, nerve and motor point blocks. Secondary work at her practice focuses on the management of pediatric onset disability.

She is the founder and president of the Dayniah Fund, a non-profit charitable foundation formed to support persons with progressive debilitating diseases who are faced with catastrophic events such as surgery or illness. The Dayniah Fund educates the public about the challenges of people with disabilities and supports research on reducing the pain and suffering caused by disabling diseases and conditions.

Dr. Shapiro serves as assistant clinical professor in the Department of Rehabilitation and Regenerative Medicine at Columbia University Medical Center.

Stem Cell Institute Speakers include:

Neil Riordan PhD Clinical Trials: Umbilical Cord Mesenchymal Stem Cell Therapy for Autism and Spinal Cord Injury

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD Stem Cell Therapy for Autoimmune Disease: MS, Rheumatoid Arthritis and Lupus

View original post here:

Stem Cell Institute Welcomes Special Guest Speaker Roberta F. Shapiro DO, FAAPM&R to Stem Cell Therapy Public Seminar ...

It was not the first study to create stem cells in this way, but it was the first to use cells sourced from a diseased adult person with the aim of producing therapy-specific cells.

FEATURE

Scientists said yesterday they had used cloning technology to make embryonic stem cells that carry a diabetic womans genes, and turned them into insulin-producing beta cells that may one day cure her disease.

The team reported clearing an important hurdle in the quest to make personalised stem cells for use in disease therapy, but a bioethicist said the breakthrough also highlighted the need for better regulation of lab-grown embryos.

We are now one step closer to being able to treat diabetic patients with their own insulin-producing cells, said Dieter Egli of the New York Stem Cell Foundation (NYSCF), who led the study published in the journal Nature.

Egli and a team had transplanted the nuclei of cells taken from the womans skin into human eggs to create stem cells, which they could then coax into becoming beta cells a shortage of which causes insulin deficiency and high blood-sugar in diabetics.

In doing so, the team confirmed a potentially important source for future cell-replacement therapy.

It was not the first study to create stem cells in this way, but it was the first to use cells sourced from a diseased adult person with the aim of producing therapy-specific cells.

Insoo Hyun, a bioethicist from the Case Western Reserve Universitys school of medicine in Cleveland, Ohio, said the research, the latest to produce embryonic stem cells that carry the genomes of living people, raised red flags.

This repeated cloning of embryos and generation of stem cells, now using cells collected from adults, increases the likelihood that human embryos will be produced to generate therapy for a specific individual, he wrote in a comment carried by Nature.

Originally posted here:

Cloning: Scientists make insulin-producing cells

Stem Cell Therapy on Radyo Klinika
Dr. Edwin Bien explains stem cell therapy on Itanong Mo Kay Doc, a segment on Radyo Klinika at Dwiz 882 AM. Sponsored by Geriamin, multivitamins and minerals...

By: maroumedia

Continued here:

Stem Cell Therapy on Radyo Klinika - Video

Purtier Deer Placenta - Stem Cell Therapy
Increasingly hectic lifestyles, bad dietary habits, stress and pollution take a toll on our bodies. As we age, metabolic syndromes and cardiovascular diseases will surface. High blood pressure,...

By: Purtier International

See the article here:

Purtier Deer Placenta - Stem Cell Therapy - Video

Phoenix, Arizona (PRWEB) April 28, 2014

Center for Joint Regeneration is now offering stem cell procedures for nonoperative rotator cuff repair with Board Certified orthopedic doctors. The regenerative medicine procedures are performed as an outpatient and involve either bone marrow derived or amniotic derived stem cell material. Call (480) 466-0980 for more information and scheduling.

Millions of Americans are affected by shoulder pain due to a rotator cuff bursitis or tendon tear. The pain may persist for months and may end up needing surgery if traditional treatments fail. These may include steroid injections, physical therapy and pain medication.

Treatment with regenerative medicine has now become available with stem cell material. The Board Certified orthopedic doctors at Center for Joint Regeneration offer stem cell procedures for rotator cuff injuries with either bone marrow or amniotic derived stem cells.

The bone marrow stem cells involve harvesting the material in a short procedure from the patient, with immediate processing to concentrate the stem cells and growth factors for injection into the shoulder. The amniotic material is obtained from consenting donors after a scheduled c-section procedure. There is no fetal tissue used at all, alleviating any ethical concerns.

Small studies to date have shown stem cell procedures to work well for pain relief and restoration of function with musculoskeletal conditions such as knee arthritis, ligament injury and tendonitis. The stem cell material includes growth factors, stem cells, hyaluronic acid and anti-inflammatory medicine as well.

Center for Joint Regeneration also offers stem cell procedures for joint arthritis, ligament injuries and tendonitis of other areas of the body as well. This helps patients avoid surgery as well as helping athletes return to sporting activities.

For more information and scheduling to discuss regenerative medicine stem cell procedure options, call (480) 466-0980.

See original here:

Center for Joint Regeneration in Phoenix Now Offering Stem Cell Procedures for Nonoperative Rotator Cuff Tendon Repair

Former Ennis Coach Sam Harrell is Back Thanks to Stem Cell Therapy
Sam Harrell won three state football championships at Ennis High School, but perhaps the toughest battle he has faced has been off the field with MS. Jeff Po...

By: Jeff Power TV Productions JPTV

Read the rest here:

Former Ennis Coach Sam Harrell is Back Thanks to Stem Cell Therapy - Video